Patient demographics and disposition
melanoma, tumour, oesophageal cancer
MELANOMA, DISEASE CHARACTERISTIC, TUMOUR, OESOPHAGEAL CANCER
The median ages (Inter Quartiles) of patients recruited to A1 and A2 were 65 (59.0–75.3) and 64.5 (53.5–68.0), respectively. In the A1 cohort, 14/16 (87.5%) of participants were male and all had a diagnosis of oesophageal cancer (6 SCC and 10 ADA). In A2, 9/20 (45%) of participants were male and the most common tumour subgroup was melanoma. Further details of baseline patient and disease characteristics of the 36 enroled patients are presented in Table In A1, all 16 patients were evaluable for primary safety analysis and 12/16 were assessable for 12-week overall RECIST efficacy analysis. In A2, 18/20 patients were evaluable for primary safety analysis and 8/20 were assessable for 12-week overall RECIST efficacy analysis.The patient flow for A1 and A2 are described in CONSORT diagrams in the 